Clinical trials: Essential Hypertension.
Essential Hypertension
In-practice Evaluation of Atacand 16mg Antihypertensive Effect
The purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure after 4 weeks of administration and the importance of administration of adequate doses
- Trial name
- NCT00802542
- Where
- 4 sites in Latvia
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Hypertension, Left Ventricular Hypertrophy
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
To compare the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of the increased size of the left ventricle in overweight patients with high blood pressure.
- Conditions
- Hypertension, Left Ventricular Hypertrophy, Overweight
- Trial name
- ALLAY (NCT00219141)
- Testing
- Aliskiren 150/300 mg, Losartan 50/100 mg
- Where
- 9 sites in United States, Argentina and 7 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis, Hypertension
A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure
To assess the effect of naproxcinod vs. naproxen on arterial blood pressure patients with osteoarthritis and controlled essential hypertension
- Trial name
- HCT3012-X-111 (NCT00662610)
- Testing
- naproxcinod 375 mg -750 mg -1125 mg bid, naproxen 250 mg - 500mg -750 mg bid
- Where
- 29 sites in United States
- Volunteers
- 120 people
- Sponsor
- NicOx
Hypertension
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
The purpose of this study is to evaluate in a randomized, double-blind fashion, the long-term safety, tolerability and efficacy profile of aliskiren compared to the active comparator enalapril in children, 6 - 17 years old with…
- Trial name
- NCT01151410
- Testing
- Aliskiren, Enalapril
- Where
- 36 sites in United States, Guatemala and 5 more
- Volunteers
- 208 people
- Sponsor
- Novartis Pharmaceuticals
Primary Hypertension
High-Intensity Transcranial Alternating Current Stimulation (Hi-tACS) for Hypertension: A Randomized Controlled Trial
This study focuses on individuals with primary hypertension, with the main objective of investigating the effectiveness and safety of high-intensity transcranial alternating current stimulation (Hi-tACS) as a non-invasive…
- Trial name
- NCT07566650
- Testing
- Active High-Intensity Transcranial Alternating Current Stimulation (Hi-tACS)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xuanwu Hospital, Beijing
Hypertension, Cardiovascular Diseases
Global Paradise System US Post Approval Study
The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood…
- Conditions
- Hypertension, Cardiovascular Diseases, Vascular Diseases
- Trial name
- US GPS (NCT06297291)
- Testing
- Paradise Ultrasound Renal Denervation Treatment
- Where
- 46 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- ReCor Medical, Inc.
Hypertension, Hypertension, Resistant to Conventional Therapy
RADIANCE Continued Access Protocol
RADIANCE CAP is a non-randomized study designed to allow for continued access to ultrasound renal denervation therapy via the Paradise System, and to allow for the on-going collection of safety and effectiveness data in subjects…
- Conditions
- Hypertension, Hypertension, Resistant to Conventional Therapy, Vascular Diseases, Cardiovascular Diseases
- Trial name
- RADIANCE CAP (NCT05017935)
- Testing
- Renal Denervation
- Where
- 40 sites in United States
- Volunteers
- 300 people
- Sponsor
- ReCor Medical, Inc.
Hypertension
High Dose BAYA1040_Nifedipine: a Long Term Combination Study
This is a clinical study evaluating the safety and efficacy of long term administration of oral BAYA1040_Nifedipine 80 mg/day (40 mg twice daily) with other antihypertensives in patients with essential hypertension who are not at…
- Trial name
- NCT01294215
- Testing
- Nifedipine (Adalat, BAYA1040)
- Where
- 4 sites in Japan
- Volunteers
- 72 people
- Sponsor
- Bayer
Hypertension
Acute Hemodynamic Effects of Cocoa Polyphenols in Subjects With Hypertension and Optimal Blood Pressure
Intake of cocoa-containing foods has been found to lower blood pressure (BP) in several clinical trials. It is supposed that the cocoa polyphenols represent the active principle, lowering BP by increasing the formation of…
- Trial name
- NCT00654862
- Testing
- cocoa polyphenols
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Cologne
Essential Hypertension
Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
The purpose of this study is to evaluate the long-term safety and tolerability of the combination of aliskiren and amlodipine given to patients with essential hypertension.
- Trial name
- NCT01237873
- Testing
- Ali/Amlo 150/2.5 mg
- Where
- 13 sites in Japan
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Micardis®. Observational Study in Patients With Essential Hypertension
This study is designed to supplement, under conditions of usual clinical practice, the data on the efficacy and safety of Micardis® collected during the clinical studies.
- Trial name
- NCT02200094
- Testing
- Low dose of Telmisartan, once daily, High dose of Telmisartan, once daily
- Volunteers
- 4,532 people
- Sponsor
- Boehringer Ingelheim
High Blood Pressure
Sticker Pad Containing Essential Oil in Volunteer With High Blood Pressure
The aims of the study were to evaluate efficacy and safety of the sticker pads containing lavender and ylang ylang oil in high blood pressure volunteers
- Trial name
- NCT05808556
- Testing
- Sticker pads containing lavender and ylang ylang oil
- Where
- Thailand
- Volunteers
- 34 people
- Sponsor
- Chulalongkorn University
Essential Hypertension, Metabolic Syndrome
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
This is a multi-center, randomized, open-label, active comparator-controlled, phase 4 clinical trial to evaluate the blood pressure control of Telmisartan or Losartan in essential hypertensive patients with metabolic syndrome
- Trial name
- PRISTINE (NCT05843162)
- Testing
- Telmisartan, Losartan
- Volunteers
- 116 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension, Dyslipidemias
Observational Study to Investigate the Effectiveness and Safety of Olostar Tab in Patients With Essential Hypertension and Dyslipidemia
The purpose of this study is to investigate the effectiveness and safety of Olostar Tab in patients with essential hypertension and dyslipidemia
- Trial name
- NCT03009721
- Testing
- Other: Not applicable-observational study
- Where
- South Korea
- Volunteers
- 9,707 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Essential Hypertension
A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of Candesartan/Amlodipine combined or alone and select better dose of CKD-330 in essential hypertension patients.
- Trial name
- NCT02206165
- Testing
- Candesartan 8mg, Candesartan 16mg, Amlodipine 5mg
- Where
- South Korea
- Volunteers
- 456 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension,Essential
Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial
The purpose of this study is: 1. To evaluate the efficacy of Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension. 2. To reveal the potiential effects of SLXMKC on vascular function and structure of patients with grade…
- Trial name
- ESCIHP (NCT06093932)
- Testing
- Songling Xuemaikang Capsules, Lifestyle intervention
- Where
- 5 sites in China
- Volunteers
- 100 people
- Sponsor
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
Primary Hyperaldosteronism
Primary Hyperaldosteronism and Ischemia-reperfusion Injury
Patients with primary hyperaldosteronism experience more cardiovascular events compared to patients with primary hypertension, independent of the blood pressure level.
- Trial name
- PHA-FMD (NCT01978132)
- Testing
- forearm ischemia and reperfusion
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Essential Hypertension
Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of various dosage combinations of lercanidipine (10 and 20 mg)and enalapril (10 and 20 mg) in comparison with their respective components and with placebo.
- Trial name
- FELT (NCT01093807)
- Testing
- Lercanidipine, Enalapril, Lercanidipine + Enalapril
- Where
- France
- Volunteers
- 1,039 people
- Sponsor
- RECORDATI GROUP
Essential Arterial Hypertension
Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
- Trial name
- NCT02493322
- Testing
- Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg, Olmesartan medoxomil 20mg + Chlortalidone 25mg, Olmesartan 20mg + hydrochlorothiazide 12,5mg
- Sponsor
- EMS
Essential Hypertension
A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects
This study is a randomized, placebo-controlled, double-blind, multi-center study to evaluate efficacy and safety of different doses of CS-3150 compared to placebo in Japanese hypertensive subjects.
- Trial name
- NCT02345044
- Testing
- CS-3150, eplerenone
- Where
- Japan
- Volunteers
- 426 people
- Sponsor
- Daiichi Sankyo